scholarly article | Q13442814 |
P50 | author | Rishu Takimoto | Q123117127 |
P2093 | author name string | Junji Kato | |
Tetsuji Takayama | |||
Yoshiro Niitsu | |||
Minoru Takahashi | |||
Takuya Matsunaga | |||
Koichi Takada | |||
Takeshi Terui | |||
Shinya Minami | |||
Ken Murakami | |||
Tsuzuku Murakami | |||
P433 | issue | 24 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | apoptotic process | Q14599311 |
P304 | page(s) | 8948-8954 | |
P577 | publication date | 2003-12-01 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors | |
P478 | volume | 63 |
Q39248784 | A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). |
Q48096055 | Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis |
Q35676767 | Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis |
Q35071254 | Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage |
Q27314528 | Acetylation of the pro-apoptotic factor, p53 in the hippocampus following cerebral ischemia and modulation by estrogen |
Q28555059 | Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells |
Q36560030 | Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein |
Q35808910 | Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma |
Q37899223 | Bugs and drugs: oncolytic virotherapy in combination with chemotherapy |
Q37096490 | Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. |
Q41832646 | Co-expression of POU4F2/Brn-3b with p53 may be important for controlling expression of pro-apoptotic genes in cardiomyocytes following ischaemic/hypoxic insults |
Q36637692 | Current trends in the development and application of molecular technologies for cancer epigenetics |
Q37291391 | DNA damage induced MutS homologue hMSH4 acetylation |
Q35861153 | FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53. |
Q34968621 | Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. |
Q39354874 | Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases |
Q26853102 | HDAC inhibitors and immunotherapy; a double edged sword? |
Q66680337 | Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus |
Q33983255 | Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights |
Q39672349 | Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression |
Q37169993 | Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms |
Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
Q41851979 | Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage |
Q34115920 | Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. |
Q27015931 | Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells |
Q42277637 | Nicotinamide nucleotide transhydrogenase (NNT) deficiency dysregulates mitochondrial retrograde signaling and impedes proliferation |
Q34145992 | Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells |
Q24669960 | Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? |
Q40066192 | Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa |
Q36685003 | Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53 K317R knock-in mouse thymocytes |
Q46262918 | SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease |
Q26749468 | SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms |
Q36956900 | Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation |
Q39429804 | Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells |
Q89169966 | Targeting Epigenetics in Cancer |
Q39113061 | The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway |
Q37676974 | The emerging role of lysine acetylation of non-nuclear proteins |
Q28592663 | The transcriptional co-activator PCAF regulates cdk2 activity |
Q33622581 | Translocation of p53 to mitochondria is regulated by its lipid binding property to anionic phospholipids and it participates in cell death control |
Q24657909 | p53 acetylation is crucial for its transcription-independent proapoptotic functions |
Search more.